{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:16:21Z","timestamp":1761581781686},"reference-count":28,"publisher":"Japanese Society of Internal Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,1,1]]},"DOI":"10.2169\/internalmedicine.0927-18","type":"journal-article","created":{"date-parts":[[2018,12,31]],"date-time":"2018-12-31T17:28:52Z","timestamp":1546277332000},"page":"101-104","source":"Crossref","is-referenced-by-count":3,"title":["Successful Treatment of Lung Adenocarcinoma with Epidermal Growth Factor Receptor Compound Mutations Involving Exon 19 Deletion and Exon 20 Insertion by Afatinib"],"prefix":"10.2169","volume":"58","author":[{"given":"Tomoyuki","family":"Ikeuchi","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Matsue Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Tokuyasu","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Matsue Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soichiro","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Matsue Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Midha A, Dearden S, McCormack R. <i>EGFR<\/i> mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMap II). Am J Cancer Res 5: 2892-2911, 2015."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kobayashi Y, Mitsudomi T. Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy. Cancer Sci 107: 1179-1186, 2016.","DOI":"10.1111\/cas.12996"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Yang JC, Sequist LV, Greater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon <i>EGFR<\/i> mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol 16: 830-838, 2015.","DOI":"10.1016\/S1470-2045(15)00026-1"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Kim EY, Cho EN, Park HS, et al. Compound <i>EGFR<\/i> mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma. Cancer Biol Ther 17: 237-245, 2016.","DOI":"10.1080\/15384047.2016.1139235"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957, 2009.","DOI":"10.1056\/NEJMoa0810699"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for <i>EGFR<\/i> mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 16: 141-151, 2015.","DOI":"10.1016\/S1470-2045(14)71173-8"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169-181, 2007.","DOI":"10.1038\/nrc2088"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Beau-Faller M, Prim N, Ruppert AM, et al. Rare <i>EGFR<\/i> exon 18 and exon 20 mutations in non-small-cell lung cancer on 10117 patients: a multicenter observational study by the French ERMETIC-IFCT network. Ann Oncol 25: 126-131, 2014.","DOI":"10.1093\/annonc\/mdt418"},{"key":"9","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.lungcan.2007.06.024","volume":"58","author":"H Sasaki","year":"2007","unstructured":"9. Sasaki H, Endo K, Takada M, et al. <i>EGFR<\/i> exon 20 insertion mutation in Japanese lung cancer. Lung Cancer 58: 324-328, 2007.","journal-title":"Lung Cancer","ISSN":"http:\/\/id.crossref.org\/issn\/0169-5002","issn-type":"print"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Wu JY, Wu SG, Yang CH, et al. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res 14: 4877-4882, 2008.","DOI":"10.1158\/1078-0432.CCR-07-5123"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Jackman DM, Miller VA, Cioffredi LA, et al. Impact of epidermal growth factor receptor and <i>KRAS<\/i> mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 15: 5267-5273, 2009.","DOI":"10.1158\/1078-0432.CCR-09-0888"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Lund-Iversen M, Kleinberg L, Fjellbirkeland L, Helland A, Brustugun OT. Clinicopathological characteristics of 11 NSCLC patients with <i>EGFR<\/i>-exon 20 mutations. J Thorac Oncol 7: 1471-1473, 2012.","DOI":"10.1097\/JTO.0b013e3182614a9d"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Oxnard GR, Lo PC, Nishino M, et al. Natural history and molecular characteristics of lung cancers harboring <i>EGFR<\/i> exon 20 insertions. J Thorac Oncol 8: 179-184, 2013.","DOI":"10.1097\/JTO.0b013e3182779d18"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Arcila ME, Nafa K, Chaft JE, et al. <i>EGFR<\/i> exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther 12: 220-229, 2013.","DOI":"10.1158\/1535-7163.MCT-12-0620"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Beau-Faller M, Prim N, Ruppert AM, et al. Rare <i>EGFR<\/i> exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Ann Oncol 25: 126-131, 2014.","DOI":"10.1093\/annonc\/mdt418"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Naidoo J, Sima CS, Rodriguez K, et al. Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib. Cancer 121: 3212-3322, 2015.","DOI":"10.1002\/cncr.29493"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Chen D, Song Z, Cheng G. Clinical efficacy of first-generation <i>EGFR<\/i>-TKIs in patients with advanced non-small-cell lung cancer harboring <i>EGFR<\/i> exon 20 mutations. Onco Targets Ther 9: 4181-4186, 2016.","DOI":"10.2147\/OTT.S108242"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Yasuda H, Kobayashi S, Costa DB. <i>EGFR<\/i> exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol 13: e23-e31, 2012.","DOI":"10.1016\/S1470-2045(11)70129-2"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Yasuda H, Park E, Yun CH, et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (<i>EGFR<\/i>) exon 20 insertion mutations in lung cancer. Sci Transl Med 5: 216ra177, 2013.","DOI":"10.1126\/scitranslmed.3007205"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated <i>EGFR<\/i>. N Engl J Med 362: 2380-2388, 2010.","DOI":"10.1056\/NEJMoa0909530"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11: 121-128, 2010.","DOI":"10.1016\/S1470-2045(09)70364-X"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced <i>EGFR<\/i> mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13: 239-246, 2012.","DOI":"10.1016\/S1470-2045(11)70393-X"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with <i>EGFR<\/i> mutations. J Clin Oncol 31: 3327-3334, 2013.","DOI":"10.1200\/JCO.2012.44.2806"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced <i>EGFR<\/i> mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12: 735-742, 2011.","DOI":"10.1016\/S1470-2045(11)70184-X"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring <i>EGFR<\/i> mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 15: 213-222, 2014.","DOI":"10.1016\/S1470-2045(13)70604-1"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Kohsaka S, Nagano M, Ueno T, et al. A method of high-throughput functional evaluation of <i>EGFR<\/i> gene variants of unknown significance in cancer. Sci Transl Med 9: eaan6566, 2017.","DOI":"10.1126\/scitranslmed.aan6566"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Yokoyama T, Kondo M, Goto Y, et al. <i>EGFR<\/i> point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification. Cancer Sci 97: 753-759, 2006.","DOI":"10.1111\/j.1349-7006.2006.00233.x"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Wu SG, Chang YL, Hsu YC, et al. Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (<i>EGFR<\/i>) mutations with the classical mutation pattern. Oncologist 13: 1276-1284, 2008.","DOI":"10.1634\/theoncologist.2008-0093"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/1\/58_0927-18\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T04:35:45Z","timestamp":1573619745000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/1\/58_0927-18\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.0927-18","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,1]]}}}